
Glucagon-like peptide-1 receptor agonists for improving quality of life and mortality in adults with heart failure with preserved ejection fraction: A systematic review and meta-analysis of efficacy and safety
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxPYXJ6TzloWHB6S1RienJOZkdwZDZQTWlGNW16djE4Ym9LTEVLSW4tVVk1YlVaQUFvaDZmeUktbUZ0blBsYjk5dHhPX0xzWXM2ZzI5aHlsNUFyUHpGUWNNZG5iVmpjUFpoRzliMzZDNW1sNVhjVEZwUl9zNDlfYkVoX25KVGYzaXI3VC1KMTlpdFAyR2JPVno1OXRVSWROODQwdTJfd0RPQkY1LWdQaS0teHdFTTVPdTdNemJ0US01dUJkQS1oNG1rOEh1MVJWM21hMGF3Ym5TU3VleHhBNDRlemo0MVgzR2RZ?oc=5" target="_blank">Glucagon-like peptide-1 receptor agonists for improving quality of life and mortality in adults with heart failure with preserved ejection fraction: A systematic review and meta-analysis of efficacy and safety</a>&nbsp;&nbsp;<font color="#6f6f6f">www.elsevier.com</font>
